Health

Patients with prostate cancer may have hope thanks to a fast-track drug that could increase their life expectancy.

Fast-track drug brings hope for prostate cancer as it could extend the life expectancy of patients whose disease has spread

  • The chance of a longer life could be increased by a third, according to trials
  • The NHS will start offering the drug to eligible patients in the coming weeks.
  • Drug already available on the NHS for patients with localized prostate cancer, but will now be offered to those whose cancer has spread.

About 9,000 men with one of the most advanced forms of prostate cancer will be eligible for a new life-extending drug, thanks to an accelerated deal.

England’s NHS will become the first healthcare provider in Europe to give darolutamide to patients whose prostate cancer has spread to other parts of the body.

Trials of the drug have shown that the chances of living longer are increased by a third in men who have not received treatment before.

The drug works by blocking androgen receptors on cancer cells, which in turn blocks the effect of testosterone that allows cancer cells to survive and multiply.

A 3D rendering of cancer cells attacking and growing in a human cell

Darolutamide, Also Known By Its Trade Name Nubeqa, Could Help Extend The Lives Of Prostate Cancer Patients

Darolutamide, also known by its trade name Nubeqa, could help extend the lives of prostate cancer patients

Darolutamide, also known by its trade name Nubeqa, is already available on the NHS for some patients who have localized prostate cancer.

This offer is now being extended to cover those whose cancer has spread after NHS England struck an early access deal.

The drug is usually taken in tablet form with food and in combination with androgen deprivation therapy (ADT) and docetaxel chemotherapy.

The trial, which was conducted at nearly 300 sites worldwide, found that patients who received darolutamide were 32.5 percent less likely to die than those who received ADT and docetaxel alone.

The health service said it will begin offering the drug to eligible prostate cancer patients within weeks. Prostate cancer is the most common cancer in men and around 47,000 people are diagnosed each year in England.

What is darolutamide?

  • Darolutamide (or Nubeqa) is a type of hormone therapy for men whose prostate cancer has stopped responding to other types of hormone therapy, but has not yet spread to other parts of the body.
  • Prostate cancer cells generally need the hormone testosterone to grow. Darolutamide works by blocking the effect of testosterone on prostate cancer cells.
  • Darolutamide will not cure prostate cancer, but it can help keep it under control. Some men have been shown to take longer before the cancer spreads to other parts of the body (advanced prostate cancer). This means that it may help delay the symptoms of advanced prostate cancer in these men and may delay the need for additional treatments such as chemotherapy.

Font: prostate cancer uk

Nearly 9,000 go on to suffer from aggressive prostate cancer that has spread to other parts of the body.

NHS executive Amanda Pritchard said: “It is fantastic that patients in England are the first in Europe to receive this treatment for a truly advanced and aggressive form of prostate cancer, thanks to the NHS’s rapid follow-up to a new medicines”.

Chiara De Biase, director of advocacy and influence for the charity Prostate Cancer UK, said: “Being told you have advanced prostate cancer can be devastating and we urgently need new treatments to help these men live longer.”

“That’s why it’s great that thousands of men have early access to darolutamide along with traditional hormone therapy and chemotherapy, which could greatly improve their survival.”

The NHS’s national cancer director, Professor Peter Johnson, said: “We know that prostate cancer is the most common form of cancer among men and it is vital that the NHS continue to diagnose patients as soon as possible and expand our arsenal. cutting-edge treatments to increase people’s chances of survival.

“This innovative treatment builds on the NHS’s ambition to improve cancer care and survival rates and will help thousands of men diagnosed with prostate cancer to live better quality lives, reducing their chances of dying by a third.” .

Show More

Merry

Merry C. Vega is a highly respected and accomplished news author. She began her career as a journalist, covering local news for a small-town newspaper. She quickly gained a reputation for her thorough reporting and ability to uncover the truth.

Related Articles

Back to top button